News

A look into the top discussions on the management of obesity at the 2022 OMA Spring Meeting, from new agents to treating special populations.

Patients with anti-HBs also had higher APRI scores, FIB-4 scores, and liver stiffness values.

Combination treatment was equal to anti-VEGF monotherapy in functional and structural outcomes in the treatment of macular edema due to BRVO.

Vutrisiran is the first and only FDA-approved treatment that’s demonstrated reversal in neuropathy impairment with subcutaneous administration once every 3 months.

Data from the first human trial of the topical cream suggests a new approach to treating cutaneous warts in adults.

Dr. Akash B. Gadani said overall treatments for managing GERD are effective.

Dr. Aric Prather discusses the pandemic, his research, and his presentation from SLEEP 2022 "Sleep in the Time of COVID: An Update on How Sleep Affects the Immune System".

New data suggest race and ethnicity, income, education, rural vs urban residence, and living in a food desert all were independently associated with poor diet quality.

The decision comes after the company announced positive phase 3 data for the combination vaccine candidate in adults aged 60 years and older.

Although a small proportion of patients from both the US and Korean centers experienced new onset facial dermatitis, investigators suggested steroid withdrawal should be considered when diagnosing erythema in patients.

Investigators note that MMP2 expression was significantly decreased in TTP-treated patients with photodamage.

Dr. Auriemma examines recent paradigm shifts in obesity care, from new pharmacotherapy options to the important role of stakeholders in reducing rates.

Smoking was not linked to colonic transit times and colonic transit was not associated with IBS symptom severity.

The study popuation had a higher visual acuity at 12 months, despite receiving fewer aflibercept injections.

Among the factors associated with psoriasis, the location of some patients from this large, Italian cohort was considered to be the most influential.

Though previous research had demonstrated an increased risk of MetS in patients with psoriasis, this study was first to consider the prevalence of the condition a global scale.

Data show myopic children experienced higher scores of depression than normally-sighted children.

Data show 1 g per day of marine ω-3 fatty acid for 5.3 years showed no effect on incident clinically diagnosed DED or reported severe DED symptoms.

Some of the favorable responses to voxelotor treatment and signs of hematologic response after voxelotor treatment included increased Hb levels, decreased reticulocyte percentage, and decreased total bilirubin.

A team of investigators observe notably improved health care cost savings among patients who initiated care more than a year prior to those who haven't at all.

While there's evidence that blue light exposure can impact an individual's circadian system, Dr. Aric Prather explains that technology is only one factor of the complex issue.

In the fourth and final episode from ADA 2022, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, take a deep dive into the meeting from their perspectives as a clinical pharmacy specialist and a nurse practitioner, including their picks for the most exciting advances in diabetes technology to come from the year’s largest diabetes meeting.

Dr. Amy Licis details recent observations regarding potential underlying neurobiological reasons for sleep disturbance in pediatric patients with ADHD or autism.

The HTRA1 and CFH risk alleles, family history of AMD, the LOC387715 risk allele, and cardiovascular disease were all linked to an increased risk of AMD.

Intravenous opioid use for VOC decreased by 52% in inpatient services between 2017-2018, while oral opioid use increased.

C1M, C3M, and C4M were significantly reduced in patients with structuring disease.

In the third special edition episode of Diabetes Dialogue: Therapeutics, Technology, & Real-World Perspectives from ADA 2022, Jasmine Gonzalvo, PharmD, joins hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, to discuss prevailing barriers in diabetes management, including access to new pharmacologic agents as well as newer diabetes technologies.

Dr. Karan Lal returns to discuss key identifiers of pediatric morphea, and how dermatologists can collaborate with doctors from different branches of medicine to treat the disease.